FDA medical journals advisory panel proposed by AMA in comments on reprint guidance.
Executive Summary
FDA MEDICAL JOURNAL ADVISORY PANEL PROPOSED BY AMA in comments on FDA's December guidance to industry on dissemination of journal reprints. The American Medical Association suggests in Jan. 17 comments that FDA should allow dissemination of articles on off-label uses. As one restriction on such dissemination, AMA suggests, FDA should require that a "journal is recognized to be of national scope and reputation, as defined by an advisory panel to the FDA" with representation from national medical societies.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth